{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:58:19Z","timestamp":1791907099812,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","award":["The study was supported by Amgen as an Investigator Sponsored Study (ISS Ref.  No: 20159460)"],"award-info":[{"award-number":["The study was supported by Amgen as an Investigator Sponsored Study (ISS Ref.  No: 20159460)"]}],"id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00198-025-07538-6","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:01:40Z","timestamp":1748257300000},"page":"1231-1237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"7538_CR1","doi-asserted-by":"publisher","unstructured":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. (1993) Am J Med 94:646\u2013650. https:\/\/doi.org\/10.1016\/0002-9343(93)90218-e","DOI":"10.1016\/0002-9343(93)90218-e"},{"key":"7538_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364\u2013376","journal-title":"Lancet"},{"key":"7538_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7538_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"7538_CR5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296","journal-title":"J Bone Miner Res"},{"key":"7538_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683","journal-title":"Eur J Endocrinol"},{"key":"7538_CR7","doi-asserted-by":"publisher","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","DOI":"10.1210\/clinem\/dgaa756"},{"key":"7538_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317","journal-title":"Nat Rev Rheumatol"},{"key":"7538_CR9","doi-asserted-by":"publisher","unstructured":"Kumar S, Wang M, Kim AS, Center JR, McDonald MM, Girgis CM (2025) Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. J Bone Miner Res. https:\/\/doi.org\/10.1093\/jbmr\/zjaf037","DOI":"10.1093\/jbmr\/zjaf037"},{"key":"7538_CR10","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u20132120","journal-title":"J Bone Miner Res"},{"key":"7538_CR11","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162","journal-title":"J Clin Endocrinol Metab"},{"key":"7538_CR12","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.2021014343","volume":"139","author":"G Goyal","year":"2022","unstructured":"Goyal G, Tazi A, Go RS et al (2022) International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood 139:2601\u20132621","journal-title":"Blood"},{"key":"7538_CR13","doi-asserted-by":"publisher","unstructured":"Georgakopoulou D, Anastasilakis AD, Makras P (2022) Adult Langerhans cell histiocytosis and the skeleton. J Clin Med 11. https:\/\/doi.org\/10.3390\/jcm11040909","DOI":"10.3390\/jcm11040909"},{"key":"7538_CR14","doi-asserted-by":"publisher","first-page":"E282","DOI":"10.1210\/jc.2014-2654","volume":"100","author":"P Makras","year":"2015","unstructured":"Makras P, Salagianni M, Revelos K, Anastasilakis AD, Schini M, Tsoli M, Kaltsas G, Andreakos E (2015) Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis. J Clin Endocrinol Metab 100:E282-286","journal-title":"J Clin Endocrinol Metab"},{"key":"7538_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.metabol.2017.01.004","volume":"69","author":"P Makras","year":"2017","unstructured":"Makras P, Tsoli M, Anastasilakis AD, Thanou M, Kaltsas G (2017) Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism 69:107\u2013111","journal-title":"Metabolism"},{"key":"7538_CR16","doi-asserted-by":"publisher","first-page":"E168","DOI":"10.1002\/ajh.26936","volume":"98","author":"P Makras","year":"2023","unstructured":"Makras P, Yavropoulou MP, Chatziioannou SN, Anastasilakis AD, Georgakopoulou D, Tsoli M, Chatzelis E, Kaltsas G (2023) Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: a prospective clinical trial. Am J Hematol 98:E168\u2013E171","journal-title":"Am J Hematol"},{"key":"7538_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","volume":"51","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC, Jang GR, Chow AT, Perez-Ruixo JJ (2012) Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 51:247\u2013260","journal-title":"Clin Pharmacokinet"},{"key":"7538_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","volume":"50","author":"L Sutjandra","year":"2011","unstructured":"Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Perez-Ruixo JJ (2011) Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 50:793\u2013807","journal-title":"Clin Pharmacokinet"},{"key":"7538_CR19","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","volume":"18","author":"S Doshi","year":"2012","unstructured":"Doshi S, Sutjandra L, Zheng J, Sohn W, Peterson M, Jang G, Chow AT, Perez-Ruixo JJ (2012) Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res 18:2648\u20132657","journal-title":"Clin Cancer Res"},{"key":"7538_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00198-023-06931-3","volume":"35","author":"P Makras","year":"2024","unstructured":"Makras P, Yavropoulou MP, Polyzos SA, Papapoulos SE, Georgakopoulou D, Papatheodorou A, Anastasilakis AD (2024) The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection. Osteoporos Int 35:365\u2013370","journal-title":"Osteoporos Int"},{"key":"7538_CR21","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31:1650\u20131663","journal-title":"Ann Oncol"},{"key":"7538_CR22","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.jbo.2022.100416","volume":"33","author":"B Cadieux","year":"2022","unstructured":"Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, Scagliotti GV, Shimizu K, Stopeck A (2022) Experience with denosumab (XGEVA(R)) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol 33:100416","journal-title":"J Bone Oncol"},{"key":"7538_CR23","doi-asserted-by":"publisher","first-page":"115048","DOI":"10.1016\/j.bone.2019.115048","volume":"129","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Makras P, Tournis S, Anastasilakis AD (2019) Off-label uses of denosumab in metabolic bone diseases. Bone 129:115048","journal-title":"Bone"},{"key":"7538_CR24","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/jbmr.4380","volume":"36","author":"ME Meier","year":"2021","unstructured":"Meier ME, Clerkx SN, Winter EM, Pereira AM, van de Ven AC, van de Sande MAJ, Appelman-Dijkstra NM (2021) Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res 36:1729\u20131738","journal-title":"J Bone Miner Res"},{"key":"7538_CR25","doi-asserted-by":"publisher","first-page":"116819","DOI":"10.1016\/j.bone.2023.116819","volume":"174","author":"MC Trojani","year":"2023","unstructured":"Trojani MC, Gensburger D, Bagouet F, Cortet B, Couture G, Marcelli C, Mehsen Cetre N, Breuil V, Chapurlat R (2023) Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study. Bone 174:116819","journal-title":"Bone"},{"key":"7538_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbspin.2019.07.010","volume":"87","author":"J Dupont","year":"2020","unstructured":"Dupont J, Laurent MR, Dedeyne L, Luyten FP, Gielen E, Dejaeger M (2020) Rebound-associated vertebral fractures after stopping denosumab: report of four cases. Joint Bone Spine 87:171\u2013173","journal-title":"Joint Bone Spine"},{"key":"7538_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","volume":"3","author":"A Tyan","year":"2019","unstructured":"Tyan A, Patel SP, Block S, Hughes T, McCowen KC (2019) Rebound vertebral fractures in a patient with lung cancer after oncology-dose denosumab discontinuation: a cautionary tale. Mayo Clin Proc Innov Qual Outcomes 3:235\u2013237","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"7538_CR28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/oncolo\/oyac213","volume":"27","author":"YM Cheung","year":"2022","unstructured":"Cheung YM, Morgans A, Hamnvik OR (2022) Bone health and denosumab discontinuation in oncology populations. Oncologist 27:998\u20131003","journal-title":"Oncologist"},{"key":"7538_CR29","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMc2214862","volume":"388","author":"LF de Castro","year":"2023","unstructured":"de Castro LF, Michel Z, Pan K et al (2023) Safety and efficacy of denosumab for fibrous dysplasia of bone. N Engl J Med 388:766\u2013768","journal-title":"N Engl J Med"},{"key":"7538_CR30","doi-asserted-by":"publisher","unstructured":"Makras P, Erickson D, Davidge-Pitts CJ et al (2024) Approach to the patient: from endocrinopathy to the diagnosis of a histiocytic disorder. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae827","DOI":"10.1210\/clinem\/dgae827"},{"key":"7538_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00223-019-00550-z","volume":"104","author":"I Hartley","year":"2019","unstructured":"Hartley I, Zhadina M, Collins MT, Boyce AM (2019) Fibrous dysplasia of bone and McCune-Albright syndrome: a bench to bedside review. Calcif Tissue Int 104:517\u2013529","journal-title":"Calcif Tissue Int"},{"key":"7538_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/bcp.13820","volume":"85","author":"M Rotman","year":"2019","unstructured":"Rotman M, Hamdy NAT, Appelman-Dijkstra NM (2019) Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone. Br J Clin Pharmacol 85:1169\u20131179","journal-title":"Br J Clin Pharmacol"},{"key":"7538_CR33","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s11154-023-09832-2","volume":"24","author":"H Bertin","year":"2023","unstructured":"Bertin H, Moussa MS, Komarova S (2023) Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis. Rev Endocr Metab Disord 24:1103\u20131119","journal-title":"Rev Endocr Metab Disord"},{"key":"7538_CR34","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1210\/jc.2018-02543","volume":"104","author":"BCJ Majoor","year":"2019","unstructured":"Majoor BCJ, Papapoulos SE, Dijkstra PDS, Fiocco M, Hamdy NAT, Appelman-Dijkstra NM (2019) Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates. J Clin Endocrinol Metab 104:6069\u20136078","journal-title":"J Clin Endocrinol Metab"},{"key":"7538_CR35","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O, The Swiss Denosumab Study G (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36:1717\u20131728","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07538-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07538-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07538-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T20:27:26Z","timestamp":1751315246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07538-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7538"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07538-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PM reports fees for lectures\/advisory boards and research grants from Amgen, ITF, and Galenica, and fees for lectures\/advisory boards from UCB, Elpen, Solgar, and Er-Kim; ADA reports lecture fees from Amgen, Bianex, Eli-Lilly, Er-Kim, Galenica, ITF, Uni-Pharma, and UCB; SEP has received consulting\/speaking fees from Amgen, Entera Bio, Qualix Dot, Radius Health, and UCB; MPY and AP have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}